Liquid paraffin light 37.8% / Isopropyl myristate 13% bath additive
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Liquid paraffin light + Isopropyl myristate
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing all 10 studies.
2010–2025
Showing all 10 studies, sorted by most relevant.
M. Moniruzzaman, Miki Tamura, Y. Tahara, et al.
International journal of pharmaceutics, 2010
- Acyclovir
- Administration, Cutaneous
- Drug Carriers
M. Moniruzzaman, N. Kamiya, M. Goto
Journal of colloid and interface science, 2010
- Acyclovir
- Pharmaceutical Preparations
- Emulsions
Md. Rafiqul Islam, S. Uddin, Md. Raihan Chowdhury, et al.
ACS applied materials & interfaces, 2021
- Administration, Cutaneous
- Choline
- Diabetes Mellitus, Experimental
Fahmida Habib Nabila, Rashedul Islam, L. Yamin, et al.
ACS Biomaterials Science & Engineering, 2024
- Administration, Cutaneous
- Insulin
- Diabetes Mellitus, Experimental
studies on three-dimensional (3D) artificial human skin and a diabetic mouse model, respectively. The ET and TET1 formulations were applied to the skin of diabetic mice at an insulin dosage of 30 IU/kg. The nanovesicle formulations significantly reduced blood glucose levels (BGLs) compared with the initial high BGL value (>150 mg/dL). The nanovesicle-treated mice maintained low BGLs for over 15 h, as opposed to only 2 h in the injection group. The ET and TET1 formulations reduced the BGLs by 62 and 34%, respectively, of the initial value. These ET and TET1 formulations have a high potential for use in commercial transdermal insulin patches, enhancing comfort and adherence in diabetes treatment.
Abstract licence: CC BY-NC-ND
S. Purna Pushkala, Rames C. Panda
Cleaner Chemical Engineering, 2023
This work explains the production of isopropyl myristate (IPM), an ester formed from the esterification reaction of myristic acid and isopropyl alcohol in a reactive-distillation column. The design of the column has been done to achieve a dual process objective of achieving product purity of 99% and reactant conversion (99%) to produce 1000 kg/hr IPM at 30°C and about 1 bar pressure conditions existing within the column. The reboiler duty comes to be 190 kW against the condenser duty of 160 kW when an entrainer, cyclohexane at 1975 kg/hr is used, which can be reduced by employing two columns. The nonlinear quaternary system is solved using NRTL thermodynamic package, and the reactive distillation column is designed. The IMC-PID-based temperature controller has been designed for a closed-loop structure to achieve safe operation and desired dynamic control behavior and simulated by using MATLAB. The column has been stable under both steady-state and dynamic conditions by stabilizing the non-linear performance of the column by the controllers. The process integration of the reactor and separator into one column has minimized a process plant's operating and investment cost.
Abstract licence: CC BY
R. Campardelli, Giulia De Negri Atanasio, C. Carotenuto, et al.
Langmuir, 2023
The Sauter mean diameter, d32, is a representative parameter in emulsions that indicates the average size of the oil droplets once the emulsion becomes stable. Several mathematical and physical approaches have been employed in the literature to seek expressions for d32 under different conditions. The present work sheds light on this rich literature and emphasizes that the characterization of emulsions is still a fertile field for investigation. In this paper, a new Π-theorem-based model to predict the normalized Sauter mean diameter for the specific case of rotor-stator emulsification is sought by applying a multiple regression analysis on experimental data of oil-in-water (O-W) emulsions produced using three different oils: paraffin, soybean oil, and isopropyl myristate, at different oil-to-water (O/W) ratios and rotor speeds. The proposed model quantifies the roles of the viscous, inertial, and interfacial tension forces, besides the O/W ratio, in the emulsification process within the turbulent inertial subrange. The developed empirical correlation is then contrasted with relevant literature models for reliability assessment; predictions of the present explicit model are proven to be more accurate for the fluid properties and the experimental conditions under study.
Abstract licence: CC BY
Tang Y, Luo Z, Ma Z, et al.
2025
- Adjuvants, Vaccine
- Adjuvants, Immunologic
- DNA, Mitochondrial
T lymphocytes (CTLs), which are essential for effective cancer vaccine performance. Inspired by natural biomolecular condensates, we developed a versatile noncovalent protein self-assembly strategy distinct from traditional approaches requiring structural domain modifications or bifunctional crosslinkers. Our methodology employs amphiphilic molecules (sodium myristate/SMA and sodium dodecyl thiolate/SDT) as molecular bridges to mediate protein‒protein interactions through hydrophobic forces and disulfide bond formation. This process generates nanoscale protein condensate (PCD) vaccines with exceptional stability. As a novel adjuvant system, these synthetic condensates significantly enhance antigen cross-presentation by optimizing key parameters: antigen loading capacity, lymph node targeting, cytosolic delivery, and lysosomal escape. Consequently, they induce robust antigen-specific CTL responses and humoral immunity, demonstrating potent antitumor efficacy. Importantly, we found that the synthetic protein condensate (PCD) alone can act as a nanoadjuvant. By increasing mitochondrial membrane permeability, PCD induces mitochondrial DNA leakage into the cytosol, activating the cGAS‒STING pathway and promoting DC maturation. This safe and scalable platform eliminates the need for complex covalent modifications or genetic engineering, and it facilitates the design of diverse modular antigens, including neoantigens and viral antigens. Given its straightforward manufacturing process and superior immunogenicity, this synthetic PCD vaccine adjuvant has significant potential for clinical application and translation.
Abstract licence: CC BY
A. Macchia, C. Zaratti, Davide Ciogli, et al.
Gels, 2024
The use of organic solvents, particularly those of a non-polar nature, is a common practice during cleaning operations in the restoration of polychrome artworks and metallic artifacts. However, these solvents pose significant risks to the health of operators and the environment. This study explores the formulation of innovative gels based on non-polar solvents and cellulose derivatives, proposing a safe and effective method for cleaning metallic artworks. The study is focused on a toxic apolar solvent, Ligroin, identified as one of the most widely used solvents in the cultural heritage treatments, and some "green" alternatives such as Methyl Myristate and Isopropyl Palmitate. The main challenge lies in overcoming the chemical incompatibility between non-polar solvents and polar thickening agents like cellulose ethers. To address this problem, the research was based on a hydrophilic-lipophilic balance (HLB) system and Hansen solubility parameters (HSPs) to select appropriate surfactants, ensuring the stability and effectiveness of the formulated gels. Stability, viscosity, and solvent release capacity of gels were analyzed using Static Light Multiple Scattering (Turbiscan), viscometry, and thermogravimetric analysis (TGA). The efficacy of cleaning in comparison with Ligroin liquid was evaluated on a metal specimen treated with various apolar protective coatings used commonly in the restoration of metallic artifacts, such as microcrystalline waxes (Reswax, Soter), acrylic resins (Paraloid B44), and protective varnishes (Incral, Regalrez). Multispectral analysis, digital optical microscopy, FTIR spectroscopy, and spectrocolorimetry allowed for the assessment of the gels' ability to remove the different protective coatings, the degree of cleaning achieved, and the presence of any residues. The results obtained highlight the ability of the formulated gels to effectively remove protective coatings from metallic artifacts. Cetyl Alcohol proved to be the most versatile surfactant to realize a stable and efficient gel. The gels based on Methyl Myristate and Isopropyl Palmitate showed promising results as "green" alternatives to Ligroin, although in some cases, they exhibited less selectivity in the removal of protective coatings.
Abstract licence: CC BY
Wen J, Shen M, Zhao H, et al.
2025
- ATP Citrate (pro-S)-Lyase
- Colorectal Neoplasms
- Drug Resistance, Neoplasm
Abstract Chemoresistance is a major challenge for colorectal cancer (CRC) therapy and is a leading cause of cancer mortality, yet the underlying molecular mechanism remains unclear. ATP citrate lyase (ACLY), a rate‐limiting enzyme of de novo lipid synthesis, plays an important role in tumor progression and chemotherapy. Here, It is demonstrated that deacetylation of ACLY is critical for chemoresistance in CRC. Through proteomic screening acetylated proteins in chemoresistant patient‐derived cells, It is identified that ACLY is deacetylated at K978 site, which induces the relocation of ACLY to the nucleus and promotes its binding to RNA‐binding protein 15 (RBM15). This facilitates N 6 ‐methyladenosine (m 6 A) methylation of NOXA (also known as PMAIP1, phorbol‐12‐myristate‐13‐acetate‐induced protein 1) and decreases the stability of NOXA mRNA, resulting in chemoresistance. With the selective inhibitor Santacruzamate A, targeting the deacetylase histone deacetylase 2 (HDAC2) to inhibit the acetylation may enhance the sensitivity of chemoresistance. These findings provide new insights into the mechanism of ACLY deacetylation promoting chemoresistance and suggest a potential therapeutic strategy to mitigate the chemoresistant effects.
Abstract licence: CC BY
Ming Song, Yuhan Xin, Sulan Cai, et al.
Catalysts, 2023
Free enzymes often face economic problems because of their non-repeatability and variability, which limit their application in industrial production. In this study, KDN lipase was immobilized with the macroporous resin LXTE-1000 and glutaraldehyde. The optimal conditions of enzyme immobilization were defined by a single factor experiment and response surface methodology (RSM). The concentration of the cross-linking agent glutaraldehyde was 0.46% (v/v), the cross-linking temperature was 25.0 °C, and the cross-linking time was 157 min. The enzyme activity of the immobilized KDN lipase after adsorption/cross-linking was 291.36 U/g, and the recovery of the enzyme activity was 9.90%. The optimal conditions for the synthesis of isopropyl myristate were catalyzed by the immobilized KDN lipase in a solvent-free system: immobilized enzyme 53 mg, reaction temperature 36.1 °C, myristic acid 228.4 mg, isopropanol 114 µL, and reaction time 18 h. The yield of isopropyl myristate was 66.62%. After ten cycles, the activity of the immobilized KDN lipase preserved more than 46.87% of its initial enzyme activity, and it demonstrated high tolerance to solvents compared to free KDN lipase.
Abstract licence: CC BY
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.